Persson Cecilia, López Alejandro, Fathali Hoda, Hoess Andreas, Rojas Ramiro, Ott Marjam Karlsson, Hilborn Jöns, Engqvist Håkan
a Div. of Applied Materials Science, Dept. Engineering Sciences, Uppsala University , Uppsala , Sweden.
b Div. of Polymer Chemistry, Dept. Chemistry, Uppsala University , Uppsala , Sweden.
Biomatter. 2016;6(1):e1133394. doi: 10.1080/21592535.2015.1133394.
With the increasing elderly population an increase in the number of bony fractures associated to age-related diseases such as osteoporosis also follows. The relatively high stiffness of the acrylic bone cements used in these patients has been suggested to give raise to a suboptimal load distribution surrounding the cement in vivo, and hence contribute to clinical complications, such as additional fractures. The aim of this study was to develop a low-modulus bone cement, based on currently used, commercially available poly(methyl methacrylate) (PMMA) cements for vertebroplasty. To this end, acrylate end-functionalized oligo(trimethylene carbonate) (oTMC) was incorporated into the cements, and the resulting compressive mechanical properties were evaluated, as well as the cytotoxic and handling properties of selected formulations. Sixteen wt%oTMC was needed in the vertebroplastic cement Osteopal V to achieve an elastic modulus of 1063 MPa (SD 74), which gave a corresponding compressive strength of 46.1 MPa (SD 1.9). Cement extracts taken at 1 and 12 hours gave a reduced MG-63 cell viability in most cases, while extracts taken at 24 hours had no significant effect on cell behavior. The modification also gave an increase in setting time, from 14.7 min (SD 1.7) to 18.0 min (SD 0.9), and a decrease in maximum polymerization temperature, from 41.5°C (SD 3.4) to 30.7°C (SD 1.4). While further evaluation of other relevant properties, such as injectability and in vivo biocompatibility, remains to be done, the results presented herein are promising in terms of approaching clinically applicable bone cements with a lower stiffness.
随着老年人口的增加,与骨质疏松症等与年龄相关疾病相关的骨骨折数量也随之增加。有人认为,这些患者使用的丙烯酸骨水泥相对较高的刚度会导致体内水泥周围的载荷分布不理想,从而导致临床并发症,如额外的骨折。本研究的目的是基于目前使用的市售聚甲基丙烯酸甲酯(PMMA)骨水泥开发一种低模量骨水泥,用于椎体成形术。为此,将丙烯酸酯端基官能化的聚三亚甲基碳酸酯(oTMC)加入到骨水泥中,并对所得的压缩力学性能以及所选配方的细胞毒性和操作性能进行评估。椎体成形骨水泥Osteopal V中需要16 wt%的oTMC才能达到1063 MPa(标准差74)的弹性模量,相应的抗压强度为46.1 MPa(标准差1.9)。在1小时和12小时提取的水泥提取物在大多数情况下会降低MG-63细胞的活力,而在24小时提取的提取物对细胞行为没有显著影响。这种改性还使凝固时间从14.7分钟(标准差1.7)增加到18.0分钟(标准差0.9),最大聚合温度从41.5°C(标准差3.4)降低到30.7°C(标准差1.4)。虽然其他相关性能,如可注射性和体内生物相容性的进一步评估仍有待进行,但本文给出的结果对于开发具有较低刚度的临床适用骨水泥来说很有前景。